Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
about
The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distributionCaged Protein Prenyltransferase Substrates: Tools for Understanding Protein PrenylationHuman T-lymphotropic virus type 1 mitochondrion-localizing protein p13II sensitizes Jurkat T cells to Ras-mediated apoptosisEffect of angiotensin II and small GTPase Ras signaling pathway inhibition on early renal changes in a murine model of obstructive nephropathy.Targeted therapies for killing tumor cells.Evaluation of alkyne-modified isoprenoids as chemical reporters of protein prenylation.Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy.Peptides with anticancer use or potential.Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia.Preventing farnesylation of the dynein adaptor Spindly contributes to the mitotic defects caused by farnesyltransferase inhibitors.New molecular targeted therapies for advanced non-small-cell lung cancer.Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group.An enzyme-coupled continuous fluorescence assay for farnesyl diphosphate synthasesClassification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma.Dapson in heterocyclic chemistry, part VIII: synthesis, molecular docking and anticancer activity of some novel sulfonylbiscompounds carrying biologically active 1,3-dihydropyridine, chromene and chromenopyridine moieties.Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.A photoactive isoprenoid diphosphate analogue containing a stable phosphonate linkage: synthesis and biochemical studies with prenyltransferasesA unique carboxyl-terminal insert domain in the hematopoietic-specific, GTPase-deficient Rho GTPase RhoH regulates post-translational processing.Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.Hematopoietic-specific Rho GTPases Rac2 and RhoH and human blood disorders.Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.RhoH participates in a multi-protein complex with the zinc finger protein kaiso that regulates both cytoskeletal structures and chemokine-induced T cells.Inhibition of malignant thyroid carcinoma cell proliferation by Ras and galectin-3 inhibitorsSynergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors.
P2860
Q24805139-0E37125C-FD28-4884-830E-1C68D573E388Q27652462-22CEE98B-90D5-450E-8479-65D5DC90C996Q33908852-8A4EA43E-B09F-47C6-845B-91DA027BF96EQ33914513-C0532F0A-10B1-433A-BF86-9D2BC35D1AC5Q33942895-B748F070-0098-43A3-AD7B-CBCFF486E033Q34679579-724C4BD9-F49D-4B3B-957E-A8081BC0B095Q34973413-9F76636F-F60C-47EE-9010-E25D7AEA401AQ35167010-36627665-7C9E-4B48-A3F6-A2131A25B8F3Q35186888-2644519E-E370-4CBC-AC1F-F5D2307C2800Q35621957-79D2979A-B023-4375-B8F0-C95C753163DFQ35667806-2FDD4AFF-B509-41F0-B1D4-0367AC60C5BEQ35729250-7869D65F-D521-42A7-887A-B1AEDB8038B1Q35870322-2D644452-718C-46D1-95FD-CC97C0A40EE1Q36370759-F1F2709A-A16D-4610-AD61-B53D29B8871CQ36527362-9398CA70-8B5B-48EB-8253-9B4E23BC6540Q36740646-EB54F44A-2EB6-43F1-B37E-3ED019BAE67AQ36922830-A51C4D35-71AE-4F9E-9834-ADA8342F37D7Q37405014-2B11F808-94C7-4C36-ACC1-610A8F8DA019Q37699439-FA112196-8653-42C9-A7A8-A8716C400BC4Q37734257-59405902-6AE9-41C0-A58D-A724266B488FQ38121356-7A759A90-1F8F-4011-A912-CD07E23CA131Q40478997-40FCD458-BA0A-4AA0-98D7-3C6B204DFCC0Q40602283-155760E4-030E-41E5-9704-C0B647D7BC67Q42367947-19002B4B-B853-47FE-88BF-A111F6DF3587Q44529443-4BD1FD3A-5D36-4667-8D8E-65CCA4AFFE69
P2860
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
@ast
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
@en
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
@nl
type
label
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
@ast
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
@en
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
@nl
prefLabel
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
@ast
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
@en
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
@nl
P2093
P1433
P1476
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
@en
P2093
Beijnen JH
Schellens JH
de Klerk GJ
P304
P356
10.1097/00001813-200103000-00001
P577
2001-03-01T00:00:00Z